Elitek

Active Ingredient(s): Rasburicase
FDA Approved: * July 12, 2002
Pharm Company: * SANOFI SYNTHELABO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Elitek Overview

Rasburicase (trade names Elitek in the US and Fasturtec in the EU) is a medication that helps to clear uric acid from the blood. It is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin. Urate oxidase is known to be present in many mammals but does not naturally occur in humans.[1] Rasburicase is produced by a genetically modified Saccharomyces cerevisiae strain. The complementary DNA (cDNA) coding for rasburicase was cloned from a strain...

Read more Elitek Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rasburicase

Recent Elitek Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Rasburicase
  • Injection: 1.5mg
  • Vial: 1.5mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Elitek: (2 results)

Sorted by National Drug Code
  • 0024-5150 Elitek Kit by Sanofi-aventis U.S. LLC
  • 0024-5151 Elitek Kit by Sanofi-aventis U.S. LLC

Other drugs which contain Rasburicase or a similar ingredient: (2 results)